Abstract
In view of the similarity in chemical structure of the available 5HT3-receptor antagonists it is assumed, whilst these agents all act at the same receptor, that failure to one agent would predict subsequent failure to all 5HT3-receptor antagonists. We conducted a randomized double blind trial of granisetron 3 mg plus dexamethasone 10 mg versus continued treatment with ondansetron 8 mg plus dexamethasone 10 mg in patients with protection failure on ondansetron 8 mg plus dexamethasone 10 mg during the first 24 hours following highly emetogenic chemotherapy. Of 40 eligible patients, 21 received ondansetron + dexamethasone and 19 received granisetron + dexamethasone. We found a significant benefit from crossing-over to granisetron after failure on ondansetron. Of the 19 patients who crossed over to granisetron, 9 patients obtained complete protection, whereas this was observed in 1 of the 21 patients continuing ondansetron, P = 0.005. These results indicate that there is no complete cross-resistance between 5HT3-receptor antagonists, and that patients who have acute protection failure on one 5HT3-receptor antagonist should be offered cross-over to another 5HT3-receptor antagonist. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Boer de M, Wit de R, Stoter G and Verweij J (1995) Possible lack of full cross-resistance of 5HT3antagonists; a pilot study. J Cancer Res Clin Oncol 121: 126–127
Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA and Grala RJ (1998) Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer 6: 237–243
Gralla RJ (1998) Antiemetic therapy. Sem Oncol 25: 577–583
Italian Group for Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6: 805–810
Kamanabrou D (1992) Intravenous granisetron establishing the optimal dose. Eur J Cancer 28A: S6–S11
Martoni A, Piana E, Strocchi E, Angelelli B, Guaraldi M, Zamagni C, Camaggi CM and Pannutti F (1998) Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis. Anticancer Res 18: 2799–2804
Morrow GR, Jane MS, Hickok JT and Rosenthal SN (1995) Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), Granisetron (Kytril), and Tropisetron (Navoban). Cancer 76: 343–357
Navari R, Gandara D, Hesketh P, Hall S, Maillard J, Ritter H, Friedman C and Fitts D (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatininduced emesis. J Clin Oncol 13: 1242–1248
Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R and Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12: 2204–2210
Perez EA, Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer RH and Fitts D (1997) Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer 5: 31–37
Perez EA, Hesketh P and Sandbach J (1998a) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16: 754–760
Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K and Friedman C (1998b) Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 4: 52–58
Ruff P, Paska W, Goedhals L, Pouillart P, Rivière A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R, Butcher M, Forster J and McQuade B (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-bline, randomized parallel-group study. Oncology 51: 113–118
Stewart A, McQuade B and Cronje JDE (1995) Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, dboule-dummy, randomized, parallel-group study. Oncology 52: 202–210
Verweij J, Wit de R and Mulder de PHM (1996) Optimal control of acute cisplatin-induced emesis. Oncology 53: 56–64
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
de Wit, R., de Boer, A., vd Linden, G. et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 85, 1099–1101 (2001). https://doi.org/10.1054/bjoc.2001.2045
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2045
This article is cited by
-
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation
Supportive Care in Cancer (2017)
-
Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan
International Journal of Clinical Oncology (2017)
-
Palonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study
BMC Pharmacology and Toxicology (2014)
-
Mise à jour des recommandations de la MASCC et de l’ESMO pour la prévention des nausées et vomissements chimio- et radio-induits: résultats de la conférence de consensus de Pérouse
Oncologie (2012)
-
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
Supportive Care in Cancer (2007)